[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sars-cov-2-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sars-cov-2-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100568646","evaluation-of-direct-antiviral-treatments-against-sars-cov-2-in-immunocompromised-patients-with-covid-19-a-g2i-study-national-multicenter-observational-and-retrospective-from-june-2023-to-april-2024-100568646",false,"NCT06683937","Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024","COV-ID","Inclusion Criteria:\n\n* Adult patients with SARS-CoV-2 in France, treated in a center participating in the study\n* Symptomatic patients for Covid-19 who have received mono- or dual therapy with nirmatrelvir\u002Fritonavir or remdesivir\n* SARS-CoV-2 positive by PCR on nasopharyngeal swab, ECBC or bronchoalveolar fluid\n* Hospitalization in a ward or day hospital for SARS-CoV-2 infection\n* Patients at very high risk of severe form of SARS-CoV-2\n\n  * Aggressive lymphomas (all types)\n  * Acute lymphocytic leukemia\n  * Acute myeloid leukemia\n  * Acute promyelocytic leukemia\n  * T-cell prolymphocytic leukemia\n  * Primary lymphoma of the central nervous system\n  * Stem cell transplant\n  * Light chain amyloidosis\n  * Chronic lymphocytic leukemia\n  * Multiple myeloma\n  * Hematopoietic stem cell transplant\n  * Solid organ transplant\n  * Being on the waiting list for an organ transplant\n  * Primary immunodeficiency;\n  * HIV patients with CD4 \\\u003C200\u002Fmm3 or with a detectable viral load\n  * Lymphopenia \\\u003C200\u002Fmm3\n  * Neutropenia \\\u003C1000\u002Fmm3 for \\> 1 week\n  * Patients receiving long-term immunosuppressive treatment (period of at least 3 months during treatment during infection) with:\n* anti-CD20 antibodies\n* anti-JAK\n* BTK inhibitors\n* azathioprine\n* cyclophosphamide\n* methotrexate\n* mycophenolate mofetil\n* CAR-T cell gene therapy\n* bi-phenotypic therapeutic antibodies\n* tacrolimus\n* sirolimus\n* long-term corticosteroids (prednisone equivalent dose \\>5mg for 3 months)\n\nExclusion Criteria:\n\n* Opposition formulated (following receipt of the study information note)\n* Patients who received convalescent plasma as first-line treatment for SARS-CoV-2 infection","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","Due to the lower virulence of circulating Omicron variants and the high seroprevalence of anti-SARS-CoV-2 antibodies, the incidence of cases and deaths related to the SARS-CoV-2 virus has significantly decreased in recent months worldwide. However, these infections remain a major public health problem in severely immunocompromised patients, who have decreased vaccine efficacy and are at higher risk of persistent SARS-CoV-2 viral shedding, relapses, secondary invasive fungal infection, intensive care unit hospitalization, and death than non-immunocompromised patients.\n\nThe research concerns adult patients at very high risk of severe SARS-CoV-2 disease, suffering from SARS-CoV-2 having resulted in hospitalization in a center participating in the study in France between June 1, 2023 and April 1, 2024 and having received mono- or dual therapy with nirmatrelvir\u002Fritonavir or remdesivir in order to carry out an evaluation of direct antiviral treatments against SARS-CoV-2 in these immunocompromised patients suffering from Covid-19.\n\nThe study consists of collecting patient care data from the medical record. Patients will be identified by practitioners at each participating French center.",[24,25],"Immunocompromised Patients","SARS-CoV-2 Disease",[27,28,29],"Immunocompromised patients","SARS-CoV-2 disease","Mono- or dual therapy with nirmatrelvir\u002Fritonavir or remdesivir","NOT_YET_RECRUITING","2025-09-05",{"date":33,"type":34},"2025-09-12","ACTUAL",{"date":36,"type":20},"2025-12-01",{"date":38,"type":20},"2026-06-01",{"name":40,"class":41},"Assistance Publique - Hôpitaux de Paris","OTHER",16]